December 4, 2023
Astellas Pharma said on December 1 that the US FDA accepted for priority review a combination of its antibody drug conjugate Padcev (enfortumab vedotin) and Merck’s PD-1 inhibitor Keytruda (pembrolizumab) as a first-line therapy for locally advanced or metastatic urothelial...read more